Azole Combinations and Multi-Targeting Drugs That Synergistically Inhibit Candidozyma auris
Journal of Fungi · 07.10.2024 · 10 (10) · 698
DOI: 10.3390/jof10100698 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Fungi, online erschienen am 07.10.2024. Verfasst von Stephanie Toepfer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sir John Walsh Research Institute, University of Otago, Dunedin 9016, New Zealand. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 214 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand, Health Research Council.
Abstract (Originalsprache)
Limited antifungal treatment options and drug resistance require innovative approaches to effectively combat fungal infections. Combination therapy is a promising strategy that addresses these pressing issues by concurrently targeting multiple cellular sites. The drug targets usually selected for combination therapy are from different cellular pathways with the goals of increasing treatment options and reducing development of resistance. However, some circumstances can prevent the implementation of combination therapy in clinical practice. These could include the increased risk of adverse effects, drug interactions, and even the promotion of drug resistance. Furthermore, robust clinical evidence supporting the superiority of combination therapy over monotherapy is limited and underscores the need for further research. Despite these challenges, synergies detected with different antifungal classes, such as the azoles and echinocandins, suggest that treatment strategies can be optimized by better understanding the underlying mechanisms. This review provides an overview of multi-targeting combination strategies with a primary focus on Candidozyma auris infections.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sir John Walsh Research Institute, University of Otago, Dunedin 9016, New Zealand.
- Institute of Hygiene and Medical Microbiology, Medical University Innsbruck, 6020 Innsbruck, Austria.
- Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.
ORCID-Profile: Michaela Lackner, Brian C Monk
Förderung
- Health Research Council of New Zealand
- Health Research Council
Zitieren
APA
Toepfer, S., Keniya, M. V., Lackner, M., & Monk, B. C. (2024). Azole Combinations and Multi-Targeting Drugs That Synergistically Inhibit Candidozyma auris. Journal of Fungi, 10(10), 698. https://doi.org/10.3390/jof10100698
Vancouver
Toepfer S, Keniya MV, Lackner M, Monk BC. Azole Combinations and Multi-Targeting Drugs That Synergistically Inhibit Candidozyma auris. Journal of Fungi. 2024;10(10):698. doi:10.3390/jof10100698
BibTeX
@article{Toepfer2024,
author = {Toepfer, Stephanie and Keniya, Mikhail V and Lackner, Michaela and Monk, Brian C},
title = {Azole Combinations and Multi-Targeting Drugs That Synergistically Inhibit Candidozyma auris},
journal = {Journal of Fungi},
year = {2024},
volume = {10},
number = {10},
pages = {698},
doi = {10.3390/jof10100698}
}
EUVIMED